Based on these two central principles of previously underappreciated biology, we are developing a new class of therapies – monoclonal microbials.
The gut is the largest part of the immune system and is a central hub of the body’s network of lymphatic vessels. Immune cells circulate through tissues of the gut via these lymphatic vessels, where they are conditioned by exposure to the contents of the gut. These conditioned immune cells may then impact disease and health at all sites of the body. Our product candidates have the potential to condition immune cells in the gut.
Our product candidates are monoclonal microbials – orally-delivered pharmaceutical compositions of single microbial strains that act through the gut-body network to potentially impact disease. Monoclonal microbials are designed to act directly on immune cells in the gut, independent of the resident microbiome. The action of our product candidates does not require colonization of the gut or changing the resident microbiome.
We have observed in preclinical studies that selected monoclonal microbials can downregulate or upregulate immune responses throughout the body by acting on the gut-body network. We believe that monoclonal microbials exert their effects through interactions with host immune cells as they pass through the gut. Based on our preclinical studies, we believe that our product candidates could significantly improve the treatment of many diseases.
We are advancing multiple monoclonal microbial product candidates into clinical studies across oncology and inflammatory diseases. These first-in-human studies are expected to begin in 2018 and to deliver 10 clinical readouts across inflammatory diseases and cancer during 2019 and 2020.
We have developed an integrated platform designed to identify individual strains of microbes capable of modulating the immune system by acting on the gut-body network when administered at pharmacologically active doses. We use the process development and formulation capabilities of our platform to develop selected microbes as clinical product candidates.
Monoclonal microbials have the potential to improve upon other approaches to drug discovery and development. The development of monoclonal microbials may improve upon the speed, cost and probability of drug discovery and development. We believe monoclonal microbials may offer new treatment possibilities for patients at all stages of disease.
Evelo is committed to working with patients and physicians to develop new therapies for a wide range of diseases. We expect to begin enrolling patients in clinical trials for certain indications in the near future. For inquiries, please contact us here.
Evelo was founded by Flagship Pioneering. Flagship VentureLabs’ innovators conceived of and developed Evelo’s foundational inventions, leading to the launch of Evelo Biosciences in July 2015. Additional investors in Evelo include, GV (the venture capital arm of Alphabet, Inc.), Celgene, Mayo Clinic and Alexandria Real Estate Equities.
HUMAN GUT-DERIVED COMMENSAL BACTERIA SUPPRESS CNS INFLAMMATORY AND DEMYELINATING DISEASE
Cell Reports - August 8, 2017
MINING THE HUMAN GUT MICROBIOTA FOR IMMUNOMODULATORY ORGANISMS
Cell - February 23, 2017
SUPPRESSION OF INFLAMMATORY ARTHRITIS BY HUMAN GUT‐DERIVED PREVOTELLA HISTICOLA IN HUMANIZED MICE
Arthritis & Rheumatology - June 23, 2016
COMMENSAL BIFIDOBACTERIUM PROMOTES ANTITUMOR IMMUNITY AND FACILITATES ANTI–PD-L1 EFFICACY
Science - November 27, 2015
EVELO BIOSCIENCES EXPANDS EXECUTIVE LEADERSHIP TEAM
Cambridge, Mass. - February 8, 2018
EVELO BIOSCIENCES ANNOUNCES ISSUANCE OF U.S. PATENT SUPPORTING MONOCLONAL MICROBIAL ONCOLOGY TRIALS
Cambridge, Mass. - January 9, 2018
EVELO BIOSCIENCES AND MAYO CLINIC COLLABORATE TO ADVANCE MONOCLONAL MICROBIALS FOR THE TREATMENT OF INFLAMMATORY AND NEUROINFLAMMATORY DISEASES
Cambridge, Mass. - November 16, 2017
EVELO BIOSCIENCES ANNOUNCES $50 MILLION SERIES B FINANCING AND EXPANSION OF BOARD AND LEADERSHIP TEAM
Cambridge, Mass. - July 11, 2017
IN THE BATTLE AGAINST CANCER, MICROBES COULD BE THE ANSWER
WIRED Health - February 6, 2018
NOT YOUR MOM’S PROBIOTIC: GOOGLE-BACKED EVELO TEAMS UP WITH MAYO CLINIC ON MICROBIOME DRUGS
ENDPOINTS NEWS - November 16, 2017
AFTER RAISING $100M, GOOGLE-BACKED EVELO LOOKS TO BLAZE A NEW TRAIL WITH MONOCLONAL MICROBIALS
ENDPOINTS NEWS - July 11, 2017
A ONE-BUG DRUG FOR THE IMMUNE SYSTEM? EVELO GETS $50M TO TEST CONCEPT
Timmerman Report - July 11, 2017